Hongjie Yang

Hongjie Yang


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2011 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
BTBao-Song Teng
Bao-Song Teng
CWChen-Dong Wang
Chen-Dong Wang
HYHongjie Yang
Hongjie Yang
JWJia-Sheng Wu
Jia-Sheng Wu
DZDan Zhang
Dan Zhang
PZPing Zhou
Ping Zhou

11 July 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DPDeng Pan
Deng Pan
DZDang Zhang
Dang Zhang
JWJiasheng Wu
Jiasheng Wu
CCCongheng Chen
Congheng Chen
ZXZhixue Xu
Zhixue Xu
PZPing Zhou
Ping Zhou
Previously, we screened a proteoglycan for anti-hyperglycemic, named FYGL, from Ganoderma Lucidum. For further research of the antidiabetic mechanisms of FYGL in vivo, the glucose homeostasis, activities of insulin-sensitive enzymes, glucose transporter expression and pancreatic function were analyzed using db/db mice as diabetic models in the present work. FYGL not only lead to a reduction in glycated hemoglobin level, but also an increase in insulin and C-peptide level, whereas a decrease in glucagons level and showed a potential for the remediation of pancreatic islets. FYGL also increased the glucokinase activities, and simultaneously lowered the phosphoenol pyruvate carboxykinase activities, accompanied by a reduction in the expression of hepatic glucose transporter protein 2, while the expression of adipose and skeletal glucose transporter protein 4 was increased. Moreover, the antioxidant enzyme activities were also increased by FYGL treatment. Thus, FYGL was an effective antidiabetic agent by enhancing insulin secretion and decreasing hepatic glucose output along with increase of adipose and skeletal muscle glucose disposal in the late stage of diabetes. Furthermore, FYGL is beneficial against oxidative stress, thereby being helpful in preventing the diabetic complications.

27 February 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LJLinong Ji
Linong Ji
XTXiaolin Tong
Xiaolin Tong
HWHongyuan Wang
Hongyuan Wang
HTHaoming Tian
Haoming Tian
HZHuimin Zhou
Huimin Zhou
EGEvidence-Based Medical Research of Xiaoke Pill Study Group
Evidence-Based Medical Research of Xiaoke Pill Study Group
Treatment of diabetes mellitus with Traditional Chinese Medicine has a long history. The aim of this study is to establish the safety and efficacy of traditional Chinese medicine combined with glibenclamide to treat type 2 diabetes mellitus. In a controlled, double blind, multicentre non-inferiority trial, 800 patients with unsatisfactory glycemic control (fasting glucose 7–13 mmol/L and HbA1c 7–11%) were randomly assigned to receive Xiaoke Pill, a compound of Chinese herbs combined with glibenclamide, or Glibenclamide in two study groups – drug naive group, and patients previously treated with metformin monotherapy (metformin group). Outcome measures at 48 weeks were the incidence and rate of hypoglycemia, mean difference in HbA1c, and proportion of patients with HbA1c<6.5%. In drug naïve group, the total hypoglycemia rate and the mild hypoglycemic episode in the Xiaoke Pill arm were 38% (p = 0.024) and 41% (p = 0.002) less compared to Glibenclamide arm; in Metformin group, the average annual rate of hypoglycemia was 62% lower in Xiaoke Pill arm (p = 0.003). Respective mean changes in HbA1c from baseline were −0.70% and −0.66% for Xiaoke Pill and Glibenclamide, with a between-group difference (95% CI) of −0.04% (−0.20, 0.12) in the drug naïve group, and those in metformin group were −0.45% and −0.59%, 0.14% (−0.12, 0.39) respectively. The respective proportions of patients with a HbA1c level <6.5% were 26.6% and 23.4% in the drug naïve group and 20.1% and 18.9% in the metformin group. In patients with type 2 diabetes and inadequate glycaemic control, treatment with Xiaoke Pill led to significant reduction in risk of hypoglycemia and similar improvements in glycemic control after 48 weeks compared to Glibenclamide. Chinese Clinical Trial Register number, ChiCTR-TRC-08000074

1 January 2014 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
DPDeng Pan
Deng Pan
DZDan Zhang
Dan Zhang
JWJiasheng Wu
Jiasheng Wu
CCCongheng Chen
Congheng Chen
ZXZhixue Xu
Zhixue Xu
PZPing Zhou
Ping Zhou

1 July 2014 in Annales d'Endocrinologie
Verified
Journal Article
Closed access
QZQiang Zhang
Qiang Zhang
LZLei Zhu
Lei Zhu
MZMin Zheng
Min Zheng
CFChaohua Fan
Chaohua Fan
YLYunhao Li
Yunhao Li
HYHongjie Yang
Hongjie Yang

27 March 2012 in British Journal of Nutrition
Verified
Journal Article
Closed access
PDF file
CWChen-Dong Wang
Chen-Dong Wang
BTBao-Song Teng
Bao-Song Teng
YHYan-Ming He
Yan-Ming He
JWJia-Sheng Wu
Jia-Sheng Wu
DPDeng Pan
Deng Pan
PZPing Zhou
Ping Zhou
Protein tyrosine phosphatase 1B (PTP1B) is implicated in the negative regulation of the insulin signalling pathway by dephosphorylating the insulin receptor (IR) and IR substrates.Ganodermalucidumhas traditionally been used for the treatment of diabetes in Chinese medicine; however, its anti-diabetic potency and mechanismin vivois still unclear. Our previously published study reported a novel proteoglycan PTP1B inhibitor, named Fudan-Yueyang-Ganoderma lucidum(FYGL) fromG. lucidum, with a half-maximal inhibitory concentration (IC50) value of 5·12 (sem0·05) μg/ml, a protein:polyglycan ratio of 17:77 and 78 % glucose in polysaccharide, and dominant amino acid residues of aspartic acid, glycine, glutamic acid, alanine, serine and threonine in protein.FYGLis capable of decreasing plasma glucose in streptozotocin-induced diabetic mice with a high safety of median lethal dose (LD50) of 6 g/kg. In the present study, C57BL/6db/dbdiabetic mice were trialed further usingFYGLas well as metformin for comparison. Oral treatment withFYGLindb/dbdiabetic mice for 4 weeks significantly (P < 0·01 or 0·05) decreased the fasting plasma glucose level, serum insulin concentration and the homeostasis model assessment of insulin resistance.FYGLalso controlled the biochemistry indices relative to type 2 diabetes-accompanied lipidaemic disorders. Pharmacology research suggests thatFYGLdecreases the plasma glucose level by the mechanism of inhibiting PTP1B expression and activity, consequently, regulating the tyrosine phosphorylation level of the IR β-subunit and the level of hepatic glycogen, thus resulting in the improvement of insulin sensitivity. Therefore,FYGLis promising as an insulin sensitiser for the therapy of type 2 diabetes and accompanied dyslipidaemia.